New drug delivery technology from MIPS acquired by Capsugel
12 January 2015
A novel drug delivery technology, developed by researchers at the Monash Institute of Pharmaceutical Sciences (MIPS), has been acquired by Capsugel, a global leader in innovative dose-form development.
Monash University and Capsugel announced today that Capsugel has acquired the intellectual property pertaining to proprietary Ionic Liquid Technology developed by researchers at MIPS led by Professors Chris Porter and Peter Scammells.
The novel technology uses lipid-like counter-ions to transform crystalline drugs into ionic liquids. This leads to significant increases in drug solubility in lipid-based liquid, semi-solid and multiparticulate formulations.
Under the terms of the agreement, the University will transfer its patent application and associated results and know-how to Capsugel, effective immediately. Capsugel will also extend its existing research collaborations with Professors Colin Pouton, Scammells and Porter at MIPS by funding additional research positions to accelerate the Ionic Liquid technology and future drug-delivery projects.
Capsugel has a long history of collaboration with MIPS based researchers in lipid-based drug delivery science. This includes co-founding the Lipid Formulation Classification System (LFCS) Consortium to advance and standardise evaluation protocols for lipid-based drug-delivery systems.
Professor Bill Charman, Director of the Monash Institute of Pharmaceutical Sciences, said the technology license and research collaboration agreement was a further and substantial step in MIPS’ decade-long partnership with Capsugel.
“We are thrilled to partner with Capsugel to advance the development of the Ionic Liquids Technology and to accelerate our current and future collaborative drug-delivery projects,” he said.
Keith Hutchison, PhD, Senior Vice President, Research & Development, Capsugel said: “Our partnership with MIPS demonstrates Capsugel’s commitment to advancing high-caliber science for improved drug delivery and better healthcare solutions.”
“The Ionic Liquids Technology will allow us to significantly increase drug solubility, reduce absorption variability, decrease excipient levels and reduce pill burden. This represents a valuable addition to our capabilities in designing and developing innovative immediate and modified-release dosage forms. Our continuing work with Monash holds great potential for additional drug-delivery innovations in the future.”
Details of the terms of the agreement were not disclosed.
ABOUT MONASH UNIVERSITY AND MIPS
Monash University is Australia's largest University and is ranked in the Top 100 World Universities according to the Times Higher Education World University Rankings. The Monash Institute of Pharmaceutical Science (MIPS) is Australia’s largest pharmaceutical sciences research program in translational drug discovery, drug delivery and drug development. Pharmacy and Pharmacology at Monash is ranked number one in the Asia-Pacific and top 10 worldwide (2014 QS World University Rankings). For additional information, visit www.monash.edu/pharm.
Capsugel is a global leader in delivering high-quality, innovative dosage forms and solutions to its customers in the health care industry. The company’s Hard Capsule business offers customers the broadest portfolio of gelatin, vegetarian, and other specialized capsule technologies. Capsugel’s Dosage Form Solutions (DFS) business utilizes an array of proprietary technologies and specialized manufacturing capabilities to solve customers’ most pressing product development challenges, including bioavailability enhancement, modified release, abuse deterrence, biotherapeutic processing, and inhalation formulation. The company's fast-to-clinic program streamlines product development from pre-formulation through clinical and commercial supply for finished dosage forms. Headquartered in Morristown, N.J., Capsugel serves more than 4,000 customers in more than 100 countries. For additional information, visit www.capsugel.com.